[go: up one dir, main page]

WO2001054733A8 - Acides nucleiques, proteines et anticorps - Google Patents

Acides nucleiques, proteines et anticorps

Info

Publication number
WO2001054733A8
WO2001054733A8 PCT/US2001/001312 US0101312W WO0154733A8 WO 2001054733 A8 WO2001054733 A8 WO 2001054733A8 US 0101312 W US0101312 W US 0101312W WO 0154733 A8 WO0154733 A8 WO 0154733A8
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
antibodies
further relates
present
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/001312
Other languages
English (en)
Other versions
WO2001054733A1 (fr
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to AU2001241404A priority Critical patent/AU2001241404A1/en
Priority to EP01912649A priority patent/EP1261380A1/fr
Priority to US09/908,711 priority patent/US20020045230A1/en
Publication of WO2001054733A1 publication Critical patent/WO2001054733A1/fr
Publication of WO2001054733A8 publication Critical patent/WO2001054733A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte: sur de nouvelles protéines: plus spécifiquement sur des molécules isolées d'acide nucléique codant pour de nouveaux polypeptides; sur de nouveaux polypeptides et anticorps se fixant à ces polypeptides; sur des vecteurs, des cellules hôtes, et des méthodes de recombinaison et de synthèse, servant à produire des polynucléotides et/ou polypeptides et anticorps humains; sur des méthodes diagnostiques et thérapeutiques permettant de diagnostiquer, traiter, prévenir et/ou pronostiquer des troubles liés à ces nouveaux polypeptides; sur des procédés de criblage permettant d'identifier les agonistes et antagonistes des polynucléotides et polypeptides de l'invention; et sur des procédés et/ou préparations inhibant ou accroissant la production et le fonctionnement des polypeptides de l'invention.
PCT/US2001/001312 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps Ceased WO2001054733A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001241404A AU2001241404A1 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins and antibodies
EP01912649A EP1261380A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
US09/908,711 US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21664700P 2000-07-07 2000-07-07
US21688000P 2000-07-07 2000-07-07
US60/216,880 2000-07-07
US60/216,647 2000-07-07
US21748700P 2000-07-11 2000-07-11
US21749600P 2000-07-11 2000-07-11
US60/217,487 2000-07-11
US60/217,496 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096400P 2000-07-26 2000-07-26
US22096300P 2000-07-26 2000-07-26
US60/220,964 2000-07-26
US60/220,963 2000-07-26
US22544700P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22451900P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US22575900P 2000-08-14 2000-08-14
US22526700P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US60/225,267 2000-08-14
US60/224,519 2000-08-14
US60/224,518 2000-08-14
US60/225,214 2000-08-14
US60/225,270 2000-08-14
US60/225,266 2000-08-14
US60/225,757 2000-08-14
US60/225,268 2000-08-14
US60/225,447 2000-08-14
US60/225,759 2000-08-14
US60/225,758 2000-08-14
US60/225,213 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22668100P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US22686800P 2000-08-22 2000-08-22
US60/227,182 2000-08-22
US60/226,681 2000-08-22
US60/226,868 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22934400P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US22934300P 2000-09-01 2000-09-01
US22934500P 2000-09-01 2000-09-01
US60/229,345 2000-09-01
US60/229,287 2000-09-01
US60/229,344 2000-09-01
US60/229,343 2000-09-01
US22950900P 2000-09-05 2000-09-05
US22951300P 2000-09-05 2000-09-05
US60/229,513 2000-09-05
US60/229,509 2000-09-05
US23043700P 2000-09-06 2000-09-06
US23043800P 2000-09-06 2000-09-06
US60/230,438 2000-09-06
US60/230,437 2000-09-06
US23124400P 2000-09-08 2000-09-08
US23124300P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US23141400P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US60/231,243 2000-09-08
US60/231,242 2000-09-08
US60/231,413 2000-09-08
US60/231,414 2000-09-08
US60/232,080 2000-09-08
US60/231,244 2000-09-08
US60/232,081 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23306400P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US23239900P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US60/232,399 2000-09-14
US60/232,400 2000-09-14
US60/233,064 2000-09-14
US60/232,398 2000-09-14
US60/233,063 2000-09-14
US60/232,401 2000-09-14
US60/232,397 2000-09-14
US60/233,065 2000-09-14
US23427400P 2000-09-21 2000-09-21
US23422300P 2000-09-21 2000-09-21
US60/234,274 2000-09-21
US60/234,223 2000-09-21
US23499700P 2000-09-25 2000-09-25
US23499800P 2000-09-25 2000-09-25
US60/234,998 2000-09-25
US60/234,997 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583600P 2000-09-27 2000-09-27
US23583400P 2000-09-27 2000-09-27
US60/235,834 2000-09-27
US60/235,836 2000-09-27
US23637000P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US23632700P 2000-09-29 2000-09-29
US23636800P 2000-09-29 2000-09-29
US23636700P 2000-09-29 2000-09-29
US60/236,369 2000-09-29
US60/236,368 2000-09-29
US60/236,327 2000-09-29
US60/236,367 2000-09-29
US60/236,370 2000-09-29
US23703900P 2000-10-02 2000-10-02
US23680200P 2000-10-02 2000-10-02
US23703800P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US23703700P 2000-10-02 2000-10-02
US60/237,038 2000-10-02
US60/237,037 2000-10-02
US60/236,802 2000-10-02
US60/237,040 2000-10-02
US60/237,039 2000-10-02
US23993500P 2000-10-13 2000-10-13
US23993700P 2000-10-13 2000-10-13
US60/239,935 2000-10-13
US60/239,937 2000-10-13
US24096000P 2000-10-20 2000-10-20
US24122100P 2000-10-20 2000-10-20
US24180800P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24178700P 2000-10-20 2000-10-20
US24178500P 2000-10-20 2000-10-20
US24180900P 2000-10-20 2000-10-20
US24178600P 2000-10-20 2000-10-20
US60/241,221 2000-10-20
US60/241,786 2000-10-20
US60/241,787 2000-10-20
US60/241,826 2000-10-20
US60/241,808 2000-10-20
US60/241,785 2000-10-20
US60/241,809 2000-10-20
US60/240,960 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24653200P 2000-11-08 2000-11-08
US24652800P 2000-11-08 2000-11-08
US24661000P 2000-11-08 2000-11-08
US24661100P 2000-11-08 2000-11-08
US24647700P 2000-11-08 2000-11-08
US24647400P 2000-11-08 2000-11-08
US24652600P 2000-11-08 2000-11-08
US24647500P 2000-11-08 2000-11-08
US24652700P 2000-11-08 2000-11-08
US24652500P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US60/246,525 2000-11-08
US60/246,613 2000-11-08
US60/246,475 2000-11-08
US60/246,611 2000-11-08
US60/246,476 2000-11-08
US60/246,524 2000-11-08
US60/246,528 2000-11-08
US60/246,474 2000-11-08
US60/246,478 2000-11-08
US60/246,609 2000-11-08
US60/246,527 2000-11-08
US60/246,610 2000-11-08
US60/246,532 2000-11-08
US60/246,477 2000-11-08
US60/246,523 2000-11-08
US60/246,526 2000-11-08
US60/249,216 2000-11-17
US60/249,244 2000-11-17
US60/249,212 2000-11-17
US60/249,213 2000-11-17
US60/249,264 2000-11-17
US60/249,208 2000-11-17
US60/249,217 2000-11-17
US60/249,299 2000-11-17
US60/249,297 2000-11-17
US60/249,215 2000-11-17
US60/249,214 2000-11-17
US60/249,211 2000-11-17
US60/249,300 2000-11-17
US60/249,210 2000-11-17
US60/249,265 2000-11-17
US60/249,207 2000-11-17
US60/249,209 2000-11-17
US60/249,245 2000-11-17
US60/249,218 2000-11-17
US60/250,160 2000-12-01
US60/250,391 2000-12-01
US60/256,719 2000-12-05
US60/251,030 2000-12-05
US60/251,988 2000-12-05
US60/251,479 2000-12-06
US60/251,856 2000-12-08
US60/251,990 2000-12-08
US60/251,868 2000-12-08
US60/251,869 2000-12-08
US60/251,989 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/908,711 Continuation-In-Part US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Publications (2)

Publication Number Publication Date
WO2001054733A1 WO2001054733A1 (fr) 2001-08-02
WO2001054733A8 true WO2001054733A8 (fr) 2001-09-07

Family

ID=27587117

Family Applications (48)

Application Number Title Priority Date Filing Date
PCT/US2001/001343 Ceased WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001337 Ceased WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001351 Ceased WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 Ceased WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001309 Ceased WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001328 Ceased WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 Ceased WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 Ceased WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001302 Ceased WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 Ceased WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001345 Ceased WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001327 Ceased WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001333 Ceased WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001356 Ceased WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001239 Ceased WO2001055301A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 Ceased WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001314 Ceased WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 Ceased WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001306 Ceased WO2001055307A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 Ceased WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001308 Ceased WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps
PCT/US2001/001348 Ceased WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 Ceased WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001354 Ceased WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001316 Ceased WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 Ceased WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001321 Ceased WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 Ceased WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 Ceased WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001352 Ceased WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 Ceased WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001355 Ceased WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001342 Ceased WO2001059064A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 Ceased WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001240 Ceased WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 Ceased WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 Ceased WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001330 Ceased WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001358 Ceased WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001317 Ceased WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001335 Ceased WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 Ceased WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 Ceased WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 Ceased WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001350 Ceased WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001340 Ceased WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001341 Ceased WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001312 Ceased WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications Before (47)

Application Number Title Priority Date Filing Date
PCT/US2001/001343 Ceased WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001337 Ceased WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001351 Ceased WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 Ceased WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001309 Ceased WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001328 Ceased WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 Ceased WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 Ceased WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001302 Ceased WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 Ceased WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001345 Ceased WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001327 Ceased WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001333 Ceased WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001356 Ceased WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001239 Ceased WO2001055301A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 Ceased WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001314 Ceased WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 Ceased WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001306 Ceased WO2001055307A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 Ceased WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001308 Ceased WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps
PCT/US2001/001348 Ceased WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 Ceased WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001354 Ceased WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001316 Ceased WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 Ceased WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001321 Ceased WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 Ceased WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 Ceased WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001352 Ceased WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 Ceased WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001355 Ceased WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001342 Ceased WO2001059064A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 Ceased WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001240 Ceased WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 Ceased WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 Ceased WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001330 Ceased WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001358 Ceased WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001317 Ceased WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001335 Ceased WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 Ceased WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 Ceased WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 Ceased WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001350 Ceased WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001340 Ceased WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001341 Ceased WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Country Status (3)

Country Link
AU (16) AU2001241406A1 (fr)
CA (37) CA2397407A1 (fr)
WO (48) WO2001055323A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same

Families Citing this family (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US6929938B2 (en) 2001-08-15 2005-08-16 Millennium Pharmaceuticals, Inc. 25501, a human transferase family member and uses therefor
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
JP2003508011A (ja) * 1999-02-25 2003-03-04 トマス・ジエフアーソン・ユニバーシテイ ヒトｆｅｚ１遺伝子である新規ガン抑制遺伝子に関する組成物、キットおよび方法
EP1157038A4 (fr) * 1999-02-26 2005-01-19 Smithkline Beecham Corp Clonage du recepteur 7tm (axor 17) du type p2y
EP1169440A4 (fr) * 1999-03-23 2004-01-14 Human Genome Sciences Inc 48 proteines humaines secretees
EP1174509A4 (fr) * 1999-03-29 2003-10-22 Kansai Tech Licensing Org Co Nouvelle cytidine desaminase
CA2380550C (fr) 1999-08-12 2011-02-01 Urogenesys, Inc. Antigene transmembranaire lectine du type c exprime dans le cancer humain de la prostate et ses utilisations
EP1892249A1 (fr) * 1999-09-01 2008-02-27 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US6617147B2 (en) 2000-04-25 2003-09-09 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US7083944B1 (en) * 1999-10-27 2006-08-01 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7005499B1 (en) * 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
EP1878796A3 (fr) * 1999-11-30 2008-01-23 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
EP1690872A3 (fr) * 1999-12-01 2006-08-23 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
CN1300781A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DE60144204D1 (de) 2000-01-26 2011-04-21 Agensys Inc 84P2A9: Prostata- und hodenspezifisches Protein, das sehr stark bei Prostatakrebs vorkommt
US6953682B2 (en) 2000-02-10 2005-10-11 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
US20020082212A1 (en) * 2000-07-20 2002-06-27 Millennium Pharmaceuticals, Inc. 7716, a novel human ATPase and uses therefor
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
US20020090705A1 (en) * 2000-07-14 2002-07-11 Rachel Meyers 62088, a novel human nucleoside phosphatase family member and uses thereof
US20020031815A1 (en) * 2000-06-26 2002-03-14 Millennium Pharmaceuticals, Inc. 46619, a novel human beta-ketoacyl synthase and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
AU2001250980A1 (en) * 2000-03-23 2001-10-03 Carmela Beger Brca-1 regulators and methods of use
AU2001245974A1 (en) 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor
US20030198953A1 (en) * 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
WO2001081586A2 (fr) * 2000-04-26 2001-11-01 Millennium Pharmaceuticals, Inc. 21657, deshydrogenase humaine a chaine courte et ses utilisations
US6808876B1 (en) 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
WO2001085921A2 (fr) * 2000-05-12 2001-11-15 Merck Patent Gmbh Nouvelle serine-threonine kinase-4
EP1158001B1 (fr) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs
AU7634301A (en) * 2000-05-26 2001-12-03 Bayer Aktiengesellschaft Regulation of human p78-like serine/threonine kinase
DE10027170A1 (de) * 2000-05-31 2001-12-13 Schering Ag Humanes PEM als Target für die Fertilitätskontrolle
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7098311B2 (en) * 2000-06-02 2006-08-29 Brigham And Women's Hospital Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors
EP1292677A2 (fr) * 2000-06-05 2003-03-19 Bayer Aktiengesellschaft Regulation du recepteur couple a la proteine humaine g de type hm74
US6323016B1 (en) 2000-06-09 2001-11-27 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
CA2411278A1 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
AU2001268435A1 (en) * 2000-06-15 2001-12-24 Millennium Pharmaceuticals, Inc. 23680, a novel human aminotransferase and uses therefor
JP2004513620A (ja) * 2000-06-16 2004-05-13 インサイト・ゲノミックス・インコーポレイテッド プロテインホスファターゼ
EP2168980A1 (fr) * 2000-06-23 2010-03-31 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
WO2002000691A2 (fr) * 2000-06-27 2002-01-03 Curagen Corporation Nouveaux polynucleotides et polypeptides codes par ceux-ci
US7094587B2 (en) 2000-06-27 2006-08-22 Millennium Pharmaceuticals, Inc. 16002 Molecules and uses therefor
AU2001271621A1 (en) 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US6900303B2 (en) 2000-06-30 2005-05-31 Millennium Pharmaceuticals, Inc. 57658, a novel human uridine kinase and uses thereof
CA2415808A1 (fr) * 2000-07-07 2002-01-17 Incyte Genomics, Inc. Transporteurs et canaux ioniques
WO2002004510A2 (fr) * 2000-07-07 2002-01-17 Incyte Genomics, Inc. Proteines liant le nucleotide guanine
WO2002006453A2 (fr) * 2000-07-18 2002-01-24 Bayer Aktiengesellschaft Regulation de protease a serine humaine de type desc1
US6740751B2 (en) 2000-07-18 2004-05-25 Board Of Regents, The University Of Texas System Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
EP1354040A2 (fr) * 2000-07-20 2003-10-22 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
AU8762901A (en) * 2000-07-25 2002-02-05 Merck Patent Gmbh Novel protein containing ring finger domaine r1p4
AU2001277200A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-cad protein and related reagents and methods of use thereof
WO2002008282A2 (fr) * 2000-07-26 2002-01-31 Stanford University Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers
US7335732B2 (en) 2000-08-01 2008-02-26 Genentech, Inc. PRO9799 polypeptides
EP1657254A3 (fr) * 2000-08-01 2006-06-07 Genentech, Inc. Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
US7402660B2 (en) 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
US20020187138A1 (en) * 2000-08-02 2002-12-12 Rachel Meyers 15368, a novel human GTP-releasing factor family member and uses therefor
US6924364B2 (en) 2000-08-04 2005-08-02 Zymogenetics, Inc. Human secreted protein, Zzp1
AU2001281252A1 (en) 2000-08-10 2002-02-18 Board Of Regents, The University Of Texas System The tumor suppressor car-1
WO2002014355A2 (fr) * 2000-08-11 2002-02-21 Merck Patent Gmbh Nouvelles protéines mekk
EP1326985A1 (fr) * 2000-08-18 2003-07-16 MERCK PATENT GmbH Identification d'un gene d'acetyltransferase n-terminale humaine
AU2001285102A1 (en) * 2000-08-21 2002-03-04 Bristol-Myers Squibb Company Adenosine deaminase homolog
US6962799B2 (en) * 2000-08-21 2005-11-08 Incyte Corporation Microtubule-associated proteins and tubulins
AU2001284655A1 (en) * 2000-08-24 2002-03-04 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides and uses thereof
CA2420902A1 (fr) * 2000-08-28 2002-03-07 Craig A. Rosen 18 proteines humaines secretees
US20040096842A1 (en) * 2000-08-28 2004-05-20 Peter Brodin Molecules involved in the regulation of insulin resistance syndrome (irs)
CA2705366A1 (fr) 2000-08-28 2002-03-07 Agensys, Inc. Acide nucleique et proteine correspondante denommes 85p1b3 utilises dans le traitement et la detection de cancers
AU2001285908A1 (en) * 2000-08-30 2002-03-13 Bayer Aktiengesellschaft Regulation of human aminotransferase-like enzyme
WO2002018567A2 (fr) * 2000-08-30 2002-03-07 Bayer Aktiengesellschaft Regulation d'enzyme humaine de type aminotransferase
WO2002018573A2 (fr) * 2000-08-30 2002-03-07 Millennium Pharmaceuticals, Inc. Nouveau transporteur humain de sulfate: la proteine 54370, et utilisations associees
AU2001286815A1 (en) * 2000-08-30 2002-03-13 Millennium Pharmaceuticals, Inc. 48921, a novel human gtp releasing factor and uses therefor
AU2001288600A1 (en) 2000-08-31 2002-03-13 Millennium Pharmaceuticals, Inc. 62112, a novel human dehydrogenase and uses thereof
WO2002020754A2 (fr) * 2000-09-05 2002-03-14 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
AU2001288812B2 (en) * 2000-09-05 2007-05-10 Amgen Inc. TNF receptor-like molecules and uses thereof
AU2001288999A1 (en) * 2000-09-08 2002-03-22 Millennium Pharmaceuticals, Inc. 38646, a guanine nucleotide exchange factor and uses therefor
US6391606B1 (en) * 2000-09-14 2002-05-21 Pe Corporation Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
US6372468B1 (en) * 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20040010119A1 (en) * 2001-02-12 2004-01-15 Xiaojia Guo Novel proteins and nucleic acids encoding same
JP2004531203A (ja) * 2000-10-05 2004-10-14 キュラジェン コーポレイション ヒトタンパク質、これらをコードするポリヌクレオチド、ならびにこれらの利用方法
WO2002031132A2 (fr) * 2000-10-11 2002-04-18 Millennium Pharmaceuticals, Inc. Nouvel element de la famille des phosphatases humaines a double specificite, appele 8843, et utilisation de ce dernier
AU2002220613A1 (en) * 2000-10-11 2002-04-22 Bayer Aktiengesellschaft Regulation of human cyclophilin-type peptidyl-prolyl cis-trans isomerase
AU2002211715A1 (en) * 2000-10-12 2002-04-22 The Texas A And M University System Nucleic acid sequences encoding cmg proteins cmg proteins and methods for their use
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
JP2004518437A (ja) 2000-10-25 2004-06-24 ディアデクサス インコーポレーテッド 肺特異的遺伝子およびタンパク質に関する組成物および方法
AU2002220668A1 (en) * 2000-10-31 2002-05-15 Bayer Aktiengesellschaft Regulation of human glutathione-s-transferase
WO2002038743A2 (fr) * 2000-11-09 2002-05-16 Glaxo Group Limited Enzyme
EP1349934A2 (fr) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions et methodes relatives a des genes et des proteines specifiques aux seins
AU2001297765A1 (en) * 2000-12-05 2002-10-21 Incyte Genomics, Inc. Ligases
WO2002046417A2 (fr) 2000-12-07 2002-06-13 Zymogenetics, Inc. Proteine associee au complement adipocyte zacrp3x2
WO2002046477A2 (fr) 2000-12-07 2002-06-13 Chiron Corporation Retrovirus endogenes regules positivement dans le cancer de la prostate
WO2002048328A2 (fr) * 2000-12-14 2002-06-20 Pe Corporation (Ny) Proteines kinases humaines isolees, molecules d'acide nucleique codant des proteines kinases humaines et utilisations associees
US20020142376A1 (en) * 2000-12-20 2002-10-03 Gennady Merkulov Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
MXPA03005500A (es) 2000-12-22 2004-04-20 Bristol Myers Squibb Co Proteina humana novedosa que contiene una repeticion rica en leucina, expresada predominantemente en intestino delgado, hlrrsi1.
US6423521B1 (en) 2000-12-28 2002-07-23 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002053591A1 (fr) * 2000-12-30 2002-07-11 Lion Bioscience Ag Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation
WO2002053754A2 (fr) * 2001-01-08 2002-07-11 Lexicon Genetics Incorporated Nouvelle protease humaine et polynucleotides codant cette derniere
WO2002061046A2 (fr) * 2001-01-30 2002-08-08 Regeneron Pharmaceuticals, Inc. Nouvelles molecules d'acide nucleique et polypeptidiques
EP1637601A3 (fr) * 2001-02-21 2006-03-29 Curagen Corporation Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation
WO2002072786A2 (fr) 2001-03-13 2002-09-19 Corvas International, Inc. Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
WO2002077263A2 (fr) 2001-03-22 2002-10-03 Dendreon San Diego Llc Molecules d'acide nucleique codant la serine protease cvsp14, polypeptides codes et procedes
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US6913904B2 (en) * 2001-03-27 2005-07-05 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
AU2002258626B2 (en) 2001-04-10 2007-01-18 Agensys, Inc. Nucleid acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
WO2002083921A2 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
AU2002303340A1 (en) 2001-04-10 2002-10-28 Agensys, Inc. Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
US20050123910A1 (en) * 2001-04-24 2005-06-09 Cookson William Osmond C.M. Enzyme and snp marker for disease
US20040175763A1 (en) * 2001-04-24 2004-09-09 Hiroshi Saito Crohn's disease antibody-binding peptide and method of examining crohn's disease
US20050158719A1 (en) * 2001-05-07 2005-07-21 Yasufumi Sato Polypeptide serving as angiogenic marker and dna thereof
WO2002090543A2 (fr) * 2001-05-09 2002-11-14 Bayer Aktiengesellschaft Régulation de la protéine semblable à celle de type 2c de la phosphatase de l'acide phosphatidique humain
WO2002092841A2 (fr) 2001-05-14 2002-11-21 Dendreon San Diego Llc Molecules d'acides nucleiques codant pour une serine protease transmembranaire 10, polypeptides codes et methodes associees
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
AU2002311535A1 (en) * 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding protein kinases
GB2399087A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ7
EP1423415A4 (fr) * 2001-08-17 2005-04-06 Incyte Genomics Inc Molecules de signalisation intercellulaire
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2003023063A1 (fr) * 2001-09-07 2003-03-20 Sankyo Company, Limited Methode d'estimation du risque d'apparition de diabetes
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025175A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
JP2005534279A (ja) 2001-09-28 2005-11-17 ブリガム ヤング ユニバーシティ 新規なシクロオキシゲナーゼ変異体とその使用方法
JPWO2003038087A1 (ja) 2001-10-04 2005-02-24 関西ティー・エル・オー株式会社 ＤＲ５遺伝子のプロモーターおよびＳｉａｈ−１遺伝子のプロモーター
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003031607A1 (fr) * 2001-10-10 2003-04-17 Bayer Healthcare Ag Regulation de deshydrogenase/reductase des chaines courtes humaine
EP1310552B1 (fr) 2001-11-09 2007-06-13 Proteologics, Inc. Acides nucléiques et polypeptides Posh et procédés associés
WO2003054146A2 (fr) 2001-11-14 2003-07-03 Northwestern University Auto-assemblage et mineralisation de nanofibres de peptide amphiphile
CA2468145A1 (fr) * 2001-11-21 2003-05-30 Japan Science And Technology Agency Facteurs de transcription de gene de la choree de huntington
US7151162B2 (en) 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
AU2002339697A1 (en) * 2001-12-19 2003-06-30 Genset S.A. Gmg-5 polynucleotides and polypeptides and uses thereof
JP2003245084A (ja) * 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
DE10163467A1 (de) * 2001-12-21 2003-11-27 Axaron Bioscience Ag Protein 24B2 und zugrundliegende DNA-Sequenz
US6759222B2 (en) 2002-01-02 2004-07-06 Millennium Pharmaceuticals, Inc. 14815, a human kinase family member and uses therefor
AU2003202543A1 (en) * 2002-01-07 2003-07-24 Bayer Aktiengesellschaft Human phosphatidic acid phosphatase type 2-like protein
AU2003235631A1 (en) * 2002-01-15 2003-07-30 Bayer Aktiengesellschaft Human subtilisin/kexin-like convertase
WO2003059948A1 (fr) * 2002-01-15 2003-07-24 Medigene Ag Gene-2 associe a la myocardiopathie dilatee (dcmag-2) : inducteur cytoplasmique du remodelage sarcomerique de cardiomyocytes
JPWO2003062429A1 (ja) * 2002-01-23 2005-05-26 山之内製薬株式会社 新規セリンプロテアーゼ
US7371719B2 (en) 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1338609A1 (fr) * 2002-02-21 2003-08-27 MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln Un outre récepteur KDR et son utilisation
AU2003225666A1 (en) * 2002-03-05 2003-09-22 Applera Corporation Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
GB2388113A (en) * 2002-03-06 2003-11-05 Oxford Glycosciences B-cell malignancy-associated protein
EP2241636A1 (fr) 2002-03-13 2010-10-20 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
US7527935B2 (en) 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
AU2003220913A1 (en) * 2002-03-19 2003-09-29 Tanabe Seiyaku Co., Ltd. Novel g protein-coupled recepotrs and genes thereof
GB0206684D0 (en) * 2002-03-21 2002-05-01 Babraham Inst Novel proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
JP2004041003A (ja) * 2002-05-17 2004-02-12 Takeda Chem Ind Ltd 新規タンパク質、そのｄｎａおよびその用途
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
US7198899B2 (en) 2002-06-03 2007-04-03 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
AU2003241179C1 (en) 2002-06-06 2010-11-25 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
ATE545651T1 (de) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic Vektoren zur expression von hml-2-polypeptiden
CA2493263A1 (fr) * 2002-07-22 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveau gene associe a l'arthrite rhumatoide
EP1551976B1 (fr) 2002-08-14 2008-12-31 National Institue of Advanced Industrial Science and Technology Nouvelles n-acetylgalactosamine transferases et acides nucleiques codant ces transferases
US20040081653A1 (en) * 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004018518A1 (fr) * 2002-08-23 2004-03-04 Japan Science And Technology Agency Peptides antigeniques de tumeur cancereuse solide humains, polynucleotides codant pour ceux-ci et utilisation de ceux-ci
EP1540014A2 (fr) * 2002-08-27 2005-06-15 Epigenomics AG Procede et acides nucleiques servant a l'analyse de troubles lies a la proliferation des cellules mammaires
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
US7601826B2 (en) * 2002-09-30 2009-10-13 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
WO2004035823A2 (fr) * 2002-10-17 2004-04-29 Evotec Neurosciences Gmbh Utilisation diagnostique et therapeutique des gene et proteine ensadin-0625 destinee a des maladies neurodegeneratives
AU2002952216A0 (en) * 2002-10-23 2002-11-07 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
WO2004046386A1 (fr) 2002-11-15 2004-06-03 Genomic Health, Inc. Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003287764B2 (en) * 2002-12-13 2010-01-21 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
AU2002953341A0 (en) * 2002-12-13 2003-01-09 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004070025A2 (fr) * 2003-02-05 2004-08-19 Juan Saus Nouvelles isoformes de la proteine liant l'antigene de goodpasture et troubles induits par une proteine incorrectement repliee
EP1445614A1 (fr) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu
US7074891B2 (en) 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
DE602004017426D1 (de) 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
EP1600458A4 (fr) * 2003-03-04 2006-10-25 Astellas Pharma Inc Nouveau gene associe a des conditions fibreuses
EA010055B1 (ru) * 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
AU2003901671A0 (en) * 2003-04-02 2003-05-01 The University Of Adelaide Comparative genomic hybridization
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2787475T3 (es) 2003-06-24 2020-10-16 Genomic Health Inc Predicción de probabilidad de recurrencia del cáncer
EP1644858B1 (fr) 2003-07-10 2017-12-06 Genomic Health, Inc. Algorithme de profile d'expression et test du pronostic du cancer
US20080153104A1 (en) 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
US20050136434A1 (en) * 2003-08-12 2005-06-23 Mai Xu Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
WO2005026314A2 (fr) * 2003-09-10 2005-03-24 Japan Science And Technology Agency Groupe de genes exprimes de facon differentielle dans des cellules de sang peripherique ainsi que procede de diagnostic et procede d'analyse mettant en oeuvre ce groupe
AU2004277342B2 (en) * 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
EP1685159B1 (fr) 2003-10-03 2012-08-01 Brigham & Women's Hospital Polypeptides de Tim-3
WO2005040791A2 (fr) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr)
US20050255560A1 (en) * 2003-11-21 2005-11-17 Zeren Gao Ztnf11, a tumor necrosis factor
ATE541580T1 (de) 2003-12-05 2012-02-15 Univ Northwestern Selbst anordnende peptid-amphiphile und relevante verfahren für die abgabe von wachstumsfaktor
ES2360113T3 (es) 2003-12-23 2011-06-01 Genomic Health, Inc. Amplificación universal de rna fragmentado.
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CA2560696C (fr) 2004-03-02 2019-06-25 The Johns Hopkins University Mutations du gene pik3ca dans les cancers humains
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005090569A1 (fr) * 2004-03-24 2005-09-29 The Council Of The Queensland Institute Of Medical Research Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations
ATE430763T1 (de) * 2004-03-30 2009-05-15 Nsgene As Therapeutische verwendung des wachstumsfaktors nsg33
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005118832A2 (fr) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl)
WO2006002437A2 (fr) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Traitement d'etats pathologiques impliquant la demyelinisation
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
ATE433991T1 (de) * 2004-08-05 2009-07-15 Toagosei Co Ltd Morbus-crohn-antikörperepitoppeptid und reagens zum testen auf morbus crohn
PL1836629T3 (pl) 2004-11-05 2020-06-15 Genomic Health, Inc. Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu
JP4939425B2 (ja) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006096614A2 (fr) 2005-03-04 2006-09-14 Northwestern University Epitopes angiogeniques de liaison a l'heparine, amphiphiles peptidiques, compositions auto-assemblees et procedes d'utilisation associes
WO2006120019A2 (fr) * 2005-05-13 2006-11-16 Centre National De La Recherche Scientifique Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
EP1907589A4 (fr) * 2005-07-26 2010-11-24 Siemens Healthcare Diagnostics Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire
WO2007037601A1 (fr) * 2005-09-28 2007-04-05 Knu-Industry Cooperation Foundation Polypeptide inhibant la transmigration de leucocytes ou la croissance et/ou la métastase de cellules cancéreuses, et une protéine de fusion de celui-ci
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
DK1969003T3 (da) 2005-12-14 2010-12-13 Hermo Pharma Ltd Anvendelser af et neurotrofisk faktor-protein
WO2008003656A2 (fr) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate
US20080108070A1 (en) * 2006-09-08 2008-05-08 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of colon cancer
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US8999634B2 (en) * 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
GB0805159D0 (en) * 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
HUE025636T2 (en) * 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
US7863021B2 (en) * 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009034661A1 (fr) * 2007-09-12 2009-03-19 Toppan Printing Co., Ltd. Procédé de diagnostic et induction d'une résistance à un virus
ES2401233T3 (es) 2007-10-17 2013-04-18 Universidad de Córdoba Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR
PL2235059T3 (pl) 2007-12-26 2015-08-31 Xencor Inc Warianty FC o zmodyfikowanym wiązaniu do FCRN
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
WO2009115612A1 (fr) * 2008-03-21 2009-09-24 Universiteit Hasselt Biomarqueurs de la polyarthrite rhumatoïde
EP2982695B1 (fr) 2008-07-09 2019-04-03 Biogen MA Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
JP5616888B2 (ja) 2008-07-24 2014-10-29 エヌエスジーン・アクティーゼルスカブＮｓＧｅｎｅ Ａ／Ｓ 成長因子ｍｅｔｒｎｌの治療的使用
EP2172211B1 (fr) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers
WO2010057069A1 (fr) 2008-11-14 2010-05-20 Gen-Probe Incorporated Compositions, kits et procédés pour la détection d’acide nucléique de campylobacter
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CA2745849A1 (fr) * 2008-12-09 2010-06-17 Alethia Biotherapeutics Inc. Nouveau variant retroviral endogene humain d'erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires
EP2419116A1 (fr) 2009-04-13 2012-02-22 North Western University Nouvelles structures peptidiques pour la régénération des cartilages et procédés pour les utiliser
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
CA2787940C (fr) 2010-01-27 2020-01-07 Massachusetts Institute Of Technology Agents polypeptidiques techniques pour la neutralisation de la grippe a large spectre ciblee
EP3903812A1 (fr) 2010-09-29 2021-11-03 Agensys, Inc. Conjugués anticorps-médicaments (adc) se liant aux protéines 191p4d12
KR101886029B1 (ko) 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
ES2677699T3 (es) 2010-12-14 2018-08-06 Hananja Ehf Actividad biológica de la proteína placentaria 13
WO2013034157A1 (fr) 2011-09-05 2013-03-14 Nsgene A/S Traitement de l'allodynie, de l'hyperalgie, de la douleur spontanée et de la douleur illusionnelle
WO2013068445A1 (fr) * 2011-11-09 2013-05-16 Sanofi Diacylglycérol lipase et applications associées
CA2947354C (fr) 2012-04-30 2024-03-19 Biocon Limited Proteines de fusion ciblees/immunomodulatrices et leurs procedes de fabrication
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
ES2704411T3 (es) 2013-03-12 2019-03-18 Biocon Ltd Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas
US9023353B2 (en) * 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
WO2015010108A1 (fr) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
WO2015050158A1 (fr) 2013-10-01 2015-04-09 国立大学法人三重大学 Vaccin d'induction de lymphocytes t contenant une séquence interépitope favorisant une présentation d'antigène
CN114106099B (zh) 2014-01-31 2024-05-24 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
WO2016112270A1 (fr) 2015-01-08 2016-07-14 Biogen Ma Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US11124766B2 (en) * 2015-06-12 2021-09-21 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
US10351869B2 (en) * 2015-09-04 2019-07-16 Synthetic Genomics, Inc. Microorganisms engineered for increased productivity
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
CN109475624A (zh) * 2016-03-29 2019-03-15 瓦尔基里治疗有限公司 染色体-1表达的结构维持的调节
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
EP3508499A1 (fr) 2018-01-08 2019-07-10 iOmx Therapeutics AG Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations
JP7514834B2 (ja) 2018-12-03 2024-07-11 アジェンシス，インコーポレイテッド 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
SG11202111616RA (en) * 2019-04-26 2021-11-29 Sangamo Therapeutics Inc Engineering aav
AU2020311579A1 (en) 2019-07-05 2022-02-03 Iomx Therapeutics Ag Antibodies binding IgC2 of IGSF11 (VSIG3) and uses thereof
WO2021034920A1 (fr) * 2019-08-20 2021-02-25 St. Jude Children's Research Hospital, Inc. Gene 2510002d24rik de microdélétion lié à la schizophrénie essentiel à la mémoire sociale
WO2021083958A1 (fr) * 2019-10-29 2021-05-06 Specialites Pet Food Nouveaux peptides induisant la satiété
CN115298203A (zh) * 2020-03-27 2022-11-04 万可真株式会社 包含vgll1肽的用于治疗癌症的组合物
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
WO2021229502A1 (fr) 2020-05-15 2021-11-18 Crispr Therapeutics Ag Arn messager codant pour cas9 destiné à être utilisé dans des systèmes d'édition du génome
EP4175668A1 (fr) 2020-07-06 2023-05-10 iOmx Therapeutics AG Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations
KR20230147078A (ko) * 2021-01-21 2023-10-20 에라스무스 유니버시티 메디컬 센터 로테르담 치료에 사용하기 위한 t 세포
WO2022178318A1 (fr) * 2021-02-18 2022-08-25 Beren Therapeutics P.B.C. Méthodes de traitement de l'hypercholestérolémie familiale hétérozygote et homozygote avec des cyclodextrines
CA3209014A1 (fr) * 2021-02-19 2022-08-25 Nuclear Rna Networks, Inc. Compositions et procedes pour moduler des reseaux de transcription de genes en fonction de sequences remanentes d'elements transposables a haute identite partagees et de transcrits de promoteur non processif et de transcrits proximaux de promoteu
WO2023287726A1 (fr) 2021-07-12 2023-01-19 Penland Foundation Traitement du cancer à l'aide de toxine botulique et d'oxyde nitreux
WO2023225602A1 (fr) * 2022-05-20 2023-11-23 Medikine, Inc. Polypeptides de liaison au récepteur de l'interleukine-18 et leurs utilisations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446240A (en) * 1981-01-30 1984-05-01 Nerenberg Samuel T Pancreas specific protein systems
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6080540A (en) * 1990-04-20 2000-06-27 Cold Spring Harbor Laboratory Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
EP0559770A4 (en) * 1990-11-26 1995-04-05 Us Commerce Cell stress transcriptional factors
US5721352A (en) * 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
US5840870A (en) * 1995-12-29 1998-11-24 Incyte Pharmaceuticals, Inc. Polynucleotides PANC1A and PANC1B associated with pancreatic cancer
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
JP3462313B2 (ja) * 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
US5998165A (en) * 1995-12-29 1999-12-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein associated with pancreatic cancer
JP2000511410A (ja) * 1996-04-29 2000-09-05 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン ナンセンス介在ｒｎａ崩壊の哺乳動物の調節因子
US6500934B1 (en) * 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
US5976834A (en) * 1997-01-09 1999-11-02 Smithkline Beecham Corporation cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor
US5925521A (en) * 1997-03-31 1999-07-20 Incyte Pharmaceuticals, Inc. Human serine carboxypeptidase
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
AU6956698A (en) * 1997-04-10 1998-10-30 Genetics Institute Inc. Secreted expressed sequence tags (sests)
IT1291110B1 (it) * 1997-04-15 1998-12-29 Istituto Europ Di Oncologia S Interattori intracellulari e specificita' di legame del dominio eh
US5948641A (en) * 1997-05-29 1999-09-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a metal response element binding protein
WO1998055620A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5972660A (en) * 1997-10-22 1999-10-26 Incyte Pharmaceuticals, Inc. Human hydroxypyruvate reductase
DE19818598A1 (de) * 1998-04-19 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe
CN1158386C (zh) * 1998-04-29 2004-07-21 吉尼西斯研究及发展有限公司 从皮肤细胞中分离的多核苷酸及其使用方法
US6262249B1 (en) * 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
CA2296792A1 (fr) * 1999-02-26 2000-08-26 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same

Also Published As

Publication number Publication date
WO2001055315A3 (fr) 2002-02-07
WO2001055367A1 (fr) 2001-08-02
CA2395295A1 (fr) 2001-08-02
CA2392438A1 (fr) 2001-08-02
WO2001055315A2 (fr) 2001-08-02
WO2001055350A8 (fr) 2001-09-07
WO2001055308A2 (fr) 2001-08-02
CA2395671A1 (fr) 2001-08-02
CA2392422A1 (fr) 2001-08-02
CA2395666A1 (fr) 2001-08-02
AU2001241413A1 (en) 2001-08-07
CA2395816A1 (fr) 2001-08-02
WO2001055206A8 (fr) 2001-12-13
WO2001055328A8 (fr) 2001-09-07
WO2001055325A8 (fr) 2001-12-13
AU2001241406A1 (en) 2001-08-07
WO2001055203A1 (fr) 2001-08-02
WO2001057182A3 (fr) 2002-03-28
CA2392428A1 (fr) 2001-08-02
WO2001055324A2 (fr) 2001-08-02
AU2001250770A1 (en) 2001-08-07
WO2001055302A2 (fr) 2001-08-02
WO2001055387A1 (fr) 2001-08-02
WO2001054733A1 (fr) 2001-08-02
WO2001055318A8 (fr) 2001-09-07
WO2001055312A3 (fr) 2002-03-14
WO2001055307A3 (fr) 2002-01-10
AU4141101A (en) 2001-08-20
CA2393002A1 (fr) 2001-08-02
WO2001055208A1 (fr) 2001-08-02
AU2001241415A1 (en) 2001-08-07
CA2395827A1 (fr) 2001-08-02
WO2001055207A1 (fr) 2001-08-02
AU2001241405A1 (en) 2001-08-07
CA2395729A1 (fr) 2001-08-02
CA2397839A1 (fr) 2001-08-02
CA2395734A1 (fr) 2001-08-02
WO2001055319A3 (fr) 2002-02-21
WO2001055201A8 (fr) 2001-09-07
WO2001055316A3 (fr) 2002-04-11
WO2001055304A8 (fr) 2001-09-07
WO2001055314A8 (fr) 2001-09-07
CA2395724A1 (fr) 2001-08-02
WO2001054473A2 (fr) 2001-08-02
WO2001055303A8 (fr) 2001-09-07
WO2001055323A2 (fr) 2001-08-02
CA2393912A1 (fr) 2001-08-02
WO2001055319A8 (fr) 2001-09-07
WO2001054474A2 (fr) 2001-08-02
WO2001055323A8 (fr) 2001-09-07
WO2001057182A2 (fr) 2001-08-09
WO2001055302A8 (fr) 2001-09-07
WO2001055318A2 (fr) 2001-08-02
WO2001055312A2 (fr) 2001-08-02
WO2001055205A1 (fr) 2001-08-02
CA2392450A1 (fr) 2001-08-16
CA2395858A1 (fr) 2001-08-02
CA2394039A1 (fr) 2001-08-02
WO2001055320A8 (fr) 2001-09-07
WO2001055200A8 (fr) 2001-09-07
WO2001055364A8 (fr) 2001-09-07
AU2001241409A1 (en) 2001-08-07
WO2001055205A8 (fr) 2001-12-13
WO2001055309A8 (fr) 2001-09-07
WO2001055314A2 (fr) 2001-08-02
WO2001055308A8 (fr) 2001-09-07
WO2001055309A2 (fr) 2001-08-02
WO2001054473A8 (fr) 2001-09-07
CA2395849A1 (fr) 2001-08-02
WO2001055316A8 (fr) 2001-09-07
WO2001055355A1 (fr) 2001-08-02
WO2001055304A2 (fr) 2001-08-02
WO2001055368A8 (fr) 2001-09-07
WO2001055325A3 (fr) 2002-07-04
WO2001054474A8 (fr) 2001-12-20
WO2001055364A3 (fr) 2002-07-04
CA2395699A1 (fr) 2001-08-02
WO2001055327A2 (fr) 2001-08-02
WO2001055322A3 (fr) 2002-07-04
WO2001055448A8 (fr) 2001-09-07
AU2001241416A1 (en) 2001-08-07
WO2001055303A3 (fr) 2001-12-20
AU2001241414A1 (en) 2001-08-07
WO2001055204A8 (fr) 2001-09-07
WO2001055327A3 (fr) 2002-02-28
WO2001055202A1 (fr) 2001-08-02
WO2001055310A3 (fr) 2001-12-27
CA2392398A1 (fr) 2001-08-02
CA2395885A1 (fr) 2001-08-02
WO2001055307A2 (fr) 2001-08-02
WO2001055448A1 (fr) 2001-08-02
WO2001055311A8 (fr) 2001-09-07
CA2395787A1 (fr) 2001-08-02
AU2001241407A1 (en) 2001-08-07
WO2001055447A8 (fr) 2001-09-07
WO2001055324A8 (fr) 2001-09-07
CA2398877A1 (fr) 2001-08-09
WO2001055364A2 (fr) 2001-08-02
WO2001055202A8 (fr) 2001-09-07
WO2001055301A8 (fr) 2001-09-07
AU2001241417A1 (en) 2001-08-07
WO2001055303A2 (fr) 2001-08-02
WO2001055163A8 (fr) 2001-09-07
WO2001055304A3 (fr) 2002-07-18
WO2001055320A2 (fr) 2001-08-02
WO2001055321A3 (fr) 2002-07-04
WO2001055204A1 (fr) 2001-08-02
WO2001055321A2 (fr) 2001-08-02
WO2001055343A8 (fr) 2001-09-07
CA2393652A1 (fr) 2001-08-02
WO2001055328A2 (fr) 2001-08-02
CA2395178A1 (fr) 2001-08-02
WO2001055163A1 (fr) 2001-08-02
WO2001055355A8 (fr) 2001-09-07
WO2001055327A8 (fr) 2001-09-07
WO2001055312A8 (fr) 2001-09-07
WO2001055201A1 (fr) 2001-08-02
WO2001055309A3 (fr) 2002-07-18
CA2395398A1 (fr) 2001-08-02
WO2001055310A2 (fr) 2001-08-02
CA2397407A1 (fr) 2001-08-02
CA2392751A1 (fr) 2001-08-02
CA2395738A1 (fr) 2002-08-02
WO2001055301A2 (fr) 2001-08-02
WO2001055200A1 (fr) 2001-08-02
WO2001055315A8 (fr) 2001-09-07
AU2001241408A1 (en) 2001-08-07
WO2001055311A2 (fr) 2001-08-02
WO2001055324A3 (fr) 2002-01-24
WO2001059064A2 (fr) 2001-08-16
WO2001055302A3 (fr) 2002-02-14
WO2001055323A3 (fr) 2002-05-10
AU4313701A (en) 2001-08-14
WO2001055307A8 (fr) 2001-09-07
WO2001055325A2 (fr) 2001-08-02
WO2001055310A8 (fr) 2001-09-07
CA2395872A1 (fr) 2001-08-02
CA2394841A1 (fr) 2001-08-02
WO2001055368A1 (fr) 2001-08-02
WO2001055203A8 (fr) 2001-09-07
CA2393618A1 (fr) 2001-08-02
AU2001241412A1 (en) 2001-08-07
CA2395403A1 (fr) 2001-08-02
WO2001055319A2 (fr) 2001-08-02
CA2395654A1 (fr) 2001-08-02
WO2001055367A8 (fr) 2001-12-20
AU2001241418A1 (en) 2001-08-07
WO2001055207A8 (fr) 2001-09-07
WO2001055321A8 (fr) 2001-09-07
WO2001055173A2 (fr) 2001-08-02
WO2001055208A8 (fr) 2001-09-07
WO2001055350A1 (fr) 2001-08-02
CA2398411A1 (fr) 2001-08-02
WO2001055328A3 (fr) 2002-07-04
WO2001055314A3 (fr) 2002-05-02
CA2395693A1 (fr) 2001-08-02
WO2001055308A3 (fr) 2002-07-04
WO2001055322A2 (fr) 2001-08-02
WO2001055447A1 (fr) 2001-08-02
WO2001055206A1 (fr) 2001-08-02
WO2001055320A3 (fr) 2002-04-11
WO2001055301A3 (fr) 2009-06-04
WO2001055322A8 (fr) 2001-09-07
AU2001241410A1 (en) 2001-08-07
WO2001055387A8 (fr) 2001-12-06
WO2001055311A3 (fr) 2002-07-04
WO2001055316A2 (fr) 2001-08-02
WO2001059064A3 (fr) 2002-03-14
WO2001055343A1 (fr) 2001-08-02
CA2392757A1 (fr) 2001-08-02
WO2001055173A8 (fr) 2001-11-29
WO2001055318A3 (fr) 2002-07-04

Similar Documents

Publication Publication Date Title
WO2001055204A8 (fr) Acides nucleiques, proteines et anticorps
WO2001090304A3 (fr) Acides nucleiques, proteines et anticorps
WO2001054472A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055306A8 (fr) Acides nucleiques, proteines, et anticorps
WO2001055326A3 (fr) Acides nucleiques, proteines et anticorps
WO2002026930A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055168A8 (fr) Acides nucleiques, proteines, et anticorps
WO2001055440A8 (fr) Acides nucleiques, proteines et anticorps
WO2002072763A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055167A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055162A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055449A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055305A3 (fr) Acides nucleiques, proteines, et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/2001 UNDER "PUBLISHED", ADD "WITH SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2395816

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001912649

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001912649

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001912649

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)